Hing Leung Sham, PhD

2011 Distinguished Alumni Award

BS in chemistry, 1974, University of Minnesota at Minneapolis
MS in physical organic chemistry, 1977, Iowa State University
PhD in synthetic organic chemistry, 1980, University of Hawai‘i at Mānoa

Hing Leung Sham, PhD, is senior vice president of Chemical Sciences at Elan Biopharmaceuticals, where he oversees drug discovery efforts for Autoimmune, Alzheimer’s and Parkinson’s, and other neurodegenerative disease therapeutics.

From 2002–2006, Sham directed medicinal chemistry research efforts in metabolic diseases, including diabetes and obesity, at Abbott Laboratories. He was the Distinguished Research Fellow there until 2006. He also has drug discovery experience in cardiovascular, oncology and infectious diseases (1983-2002). Sham is the primary inventor of Kaletra®, Abbott’s advanced-generation protease inhibitor for the treatment of HIV infection (more than 30 million prescriptions produced globally since launch), and a co-inventor of Norvir® (ritonavir), Abbott’s first-generation protease inhibitor.

An expert in medicinal chemistry and drug discovery, Sham is a named inventor on 75 issued U.S. patents and multiple pending U.S. patents, and he is author/co-author on more than 160 scientific publications. He is a member of numerous professional associations, and served on the editorial board for the journal Current Medicinal Chemistry.

While at Abbott, Sham received the 1995 President’s Award, 1999 Outstanding Researcher of the Year Award and the 2002 Chairman’s Award. He was named National Inventor of the Year by the Intellectual Property Owners Association in 1997, and was named Inventor of the Year in 1997 and 2004 by the Intellectual Property Law Association of Chicago. Sham received the 2003 Heroes of Chemistry Award from the American Chemical Society.